Antibody fragments are used in the clinic as important therapeutic proteins for treatment of
indications where better tissue penetration and less immunogenic molecules are needed …

Recombinant antibody fragments are being used for the last few years as an important
therapeutic protein to cure various critical and life threatening human diseases. Several …

Engineered antibodies are key players in therapy, diagnostics and research. In addition to
full size immunoglobulin gamma (IgG) molecules, smaller formats of recombinant …

At present, single-chain variable fragments (scFv) of antibodies are considered one of the
most important tools in human therapies. Wide applications of antibodies are being …

After the appearance of the first FDA‐approved antibody 25 years ago, antibodies have
become major therapeutic agents in the treatment of many human diseases, including …

With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …

Antibody technology has gone through a long evolution. This review summarizes crucial
events during the development of this expanding field, with emphasis on recent advances in …

In recent years, monoclonal antibodies have emerged as an increasingly important class of
human therapeutics. A variety of forms of antibodies, including fragments such as Fabs …

Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …

Background The production of recombinant monoclonal antibodies in mammalian cell
culture is of high priority in research and medical fields. A critical step in this process is the …